JENNA SHERIDAN: Open Payments
NPI 1912367517 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,508 in 73 payments from 14 companies in 2025. Trend: 2023 $1,281 · 2024 $1,182 · 2025 $1,508
Food & beverage: $1,508
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 13 | $250 |
| ABBVIE INC. | 16 | $239 |
| Janssen Biotech, Inc. | 11 | $184 |
| UCB, Inc. | 2 | $144 |
| Amgen Inc. | 5 | $142 |
| Lilly USA, LLC | 6 | $127 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $96 |
| Galderma Laboratories, L.P. | 5 | $94 |
| Novartis Pharmaceuticals Corporation | 3 | $80 |
| GENZYME CORPORATION | 2 | $54 |
Products named: OPZELURA, TREMFYA, SKYRIZI, Bimzelx, Otezla, TALTZ, DUPIXENT, RINVOQ.
Industry payments across MA — which companies pay providers there.
